Birchview Capital, LP Buys Bristol-Myers Squibb Company, Harrow Health Inc, Harrow Health Inc, Sells Harrow Health Inc, Atara Biotherapeutics Inc, Veracyte Inc

Burlington, VT, based Investment company Birchview Capital, LP buys Bristol-Myers Squibb Company, Harrow Health Inc, Harrow Health Inc, Intercept Pharmaceuticals Inc, Amarin Corp PLC, Lexicon Pharmaceuticals Inc, Myriad Genetics Inc, Dermira Inc, OncoMed Pharmaceuticals Inc, Immunogen Inc, Livent Corp, XBiotech Inc, Dova Pharmaceuticals Inc, sells Harrow Health Inc, Atara Biotherapeutics Inc, Veracyte Inc, AMAG Pharmaceuticals Inc, SITO Mobile during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Birchview Capital, LP. As of 2019Q1, Birchview Capital, LP owns 52 stocks with a total value of $159 million. These are the details of the buys and sells.

For the details of Birchview Capital, LP's stock buys and sells, go to https://www.gurufocus.com/guru/birchview+capital%2C+lp/current-portfolio/portfolio

These are the top 5 holdings of Birchview Capital, LP
  1. Celgene Corp (CELG) - 699,011 shares, 41.48% of the total portfolio.
  2. Accelerate Diagnostics Inc (AXDX) - 2,183,795 shares, 28.88% of the total portfolio.
  3. Clementia Pharmaceuticals Inc (CMTA) - 222,000 shares, 3.64% of the total portfolio.
  4. Neurocrine Biosciences Inc (NBIX) - 55,000 shares, 3.05% of the total portfolio.
  5. Array BioPharma Inc (ARRY) - 168,000 shares, 2.58% of the total portfolio.
New Purchase: Bristol-Myers Squibb Company (BMY)

Birchview Capital, LP initiated holding in Bristol-Myers Squibb Company. The purchase prices were between $45.12 and $53.8, with an estimated average price of $49.88. The stock is now traded at around $48.62. The impact to a portfolio due to this purchase was 0.6%. The holding were 20,000 shares as of .

New Purchase: Harrow Health Inc (3IP)

Birchview Capital, LP initiated holding in Harrow Health Inc. The purchase prices were between $4.12 and $6.16, with an estimated average price of $5.27. The stock is now traded at around $3.96. The impact to a portfolio due to this purchase was 0.56%. The holding were 180,000 shares as of .

New Purchase: Harrow Health Inc (3IP)

Birchview Capital, LP initiated holding in Harrow Health Inc. The purchase prices were between $4.12 and $6.16, with an estimated average price of $5.27. The stock is now traded at around $3.96. The impact to a portfolio due to this purchase was 0.56%. The holding were 180,000 shares as of .

New Purchase: Dermira Inc (DERM)

Birchview Capital, LP initiated holding in Dermira Inc. The purchase prices were between $6.19 and $14.13, with an estimated average price of $8.29. The stock is now traded at around $10.23. The impact to a portfolio due to this purchase was 0.17%. The holding were 20,000 shares as of .

New Purchase: Livent Corp (LTHM)

Birchview Capital, LP initiated holding in Livent Corp. The purchase prices were between $12.09 and $14.56, with an estimated average price of $13.04. The stock is now traded at around $11.29. The impact to a portfolio due to this purchase was 0.08%. The holding were 10,000 shares as of .

New Purchase: XBiotech Inc (XBIT)

Birchview Capital, LP initiated holding in XBiotech Inc. The purchase prices were between $5.05 and $11.62, with an estimated average price of $8.04. The stock is now traded at around $9.20. The impact to a portfolio due to this purchase was 0.07%. The holding were 10,000 shares as of .

Added: Intercept Pharmaceuticals Inc (ICPT)

Birchview Capital, LP added to a holding in Intercept Pharmaceuticals Inc by 93.02%. The purchase prices were between $91.83 and $120.68, with an estimated average price of $109.22. The stock is now traded at around $89.92. The impact to a portfolio due to this purchase was 0.28%. The holding were 8,300 shares as of .

Added: Amarin Corp PLC (AMRN)

Birchview Capital, LP added to a holding in Amarin Corp PLC by 47.50%. The purchase prices were between $12.61 and $22.33, with an estimated average price of $17.95. The stock is now traded at around $18.14. The impact to a portfolio due to this purchase was 0.25%. The holding were 59,000 shares as of .

Added: Lexicon Pharmaceuticals Inc (LXRX)

Birchview Capital, LP added to a holding in Lexicon Pharmaceuticals Inc by 300.00%. The purchase prices were between $4.36 and $7.94, with an estimated average price of $6.1. The stock is now traded at around $6.56. The impact to a portfolio due to this purchase was 0.21%. The holding were 80,000 shares as of .

Added: Myriad Genetics Inc (MYGN)

Birchview Capital, LP added to a holding in Myriad Genetics Inc by 100.00%. The purchase prices were between $26.93 and $34.7, with an estimated average price of $30.42. The stock is now traded at around $34.34. The impact to a portfolio due to this purchase was 0.21%. The holding were 20,000 shares as of .

Added: OncoMed Pharmaceuticals Inc (OMED)

Birchview Capital, LP added to a holding in OncoMed Pharmaceuticals Inc by 115.90%. The purchase prices were between $0.71 and $1.04, with an estimated average price of $0.81. The stock is now traded at around $0.89. The impact to a portfolio due to this purchase was 0.13%. The holding were 372,557 shares as of .

Added: Immunogen Inc (IMGN)

Birchview Capital, LP added to a holding in Immunogen Inc by 309.09%. The purchase prices were between $2.41 and $5.91, with an estimated average price of $4.37. The stock is now traded at around $2.88. The impact to a portfolio due to this purchase was 0.11%. The holding were 90,000 shares as of .

Sold Out: Harrow Health Inc (HROW)

Birchview Capital, LP sold out a holding in Harrow Health Inc. The sale prices were between $4.75 and $7.1, with an estimated average price of $6.04.

Sold Out: AMAG Pharmaceuticals Inc (AMAG)

Birchview Capital, LP sold out a holding in AMAG Pharmaceuticals Inc. The sale prices were between $11.29 and $17.05, with an estimated average price of $14.96.



Here is the complete portfolio of Birchview Capital, LP. Also check out:

1. Birchview Capital, LP's Undervalued Stocks
2. Birchview Capital, LP's Top Growth Companies, and
3. Birchview Capital, LP's High Yield stocks
4. Stocks that Birchview Capital, LP keeps buying